Abstract 555P
Background
Approximately half of non-small cell lung cancer (NSCLC) patients are diagnosed at a metastatic stage. Molecular testing is vital for identifying druggable mutations in these patients. This prospective study aimed to assess the quality of life (QoL) of these patients and differences in QoL between patients with or without druggable mutations.
Methods
Patients newly diagnosed with stage IV NSCLC after March 2021 from the seven public oncology centres in Hong Kong were eligible. Mutation profiling was performed using next-generation sequencing with FoundationOne CDx. QoL assessments were conducted at baseline and then at 3, 6, 9, and 12 months using validated EORTC QLQ-C30 and EQ-5D-5L questionnaires.
Results
A total of 580 patients were included. Statistically significant changes in various aspects of QoL were observed over time, including global health status (QL), physical functioning (PF), role functioning (RF), emotional functioning (EF), social functioning (SF), as well as symptoms such as fatigue, pain, dyspnoea, and insomnia (all p < 0.05). There was also significant change in all 5 aspects of EQ-5D-5L and utility score over time. Overall, most improvements in functional and symptom scales were observed in the first 3-6 months’ follow-up. Among the 241 patients with at least 3 months’ follow-up, compared to those without druggable mutations, those with druggable mutations demonstrated better QL at 3- and 12-month (mean difference (MD) 6.11, p=0.04; MD 19.56, p=0.01, respectively), PF at 3-, 6-, and 12-month (MD 12.76, p=0.001; MD 14.62, p=0.01; MD 22.55, p=0.02), EF at 12-month (MD 21.76, p = 0.001), and SF at 6- and 12-month (MD 14.51, p=0.02; MD 21.86, p=0.04); improved pain at 6- and 12-month (MD 14.44, p = 0.03; MD 36.57, p = 0.02), dyspnoea at 3-month (MD 18.23, p<0.001) and appetite at 6-month (MD 15.23, p = 0.04). They also had higher utility scores at 3- and 6-month intervals (MD 0.13, p = 0.04; MD 0.23, p = 0.05).
Conclusions
In conclusion, this study demonstrated improvements in QoL and symptom relief in newly diagnosed stage IV NSCLC patients within the first 3-6 months in Hong Kong. Patients with druggable mutations generally experienced better QoL compared to those without.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Hong Kong.
Funding
Roche.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract